Literature DB >> 2826604

Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes.

W M Sullender1, L L Yasukawa, M Schwartz, L Pereira, P A Hensleigh, C G Prober, A M Arvin.   

Abstract

We used a murine monoclonal antibody to herpes simplex virus (HSV) type 2 (HSV-2) glycoprotein G (gG) to develop an enzyme immunoassay that detected HSV-2 type-specific antibodies in human sera. Antibodies to HSV-2 gG were detected in 98 (96%) of 102 sera from pregnant women with culture-proved HSV-2 infection. Sixty-five percent of the women had serological evidence of past HSV-2 infection by the Rawls index, based on titers of neutralizing antibody to HSV type 1 and HSV-2. Thirty (88%) of 34 infants exposed to maternal HSV infection at delivery had antibodies to HSV-2 gG and remained well. One infant exposed to primary maternal HSV-2 infection lacked antibodies to HSV-2 gG and developed neonatal HSV-2 infection. The mean +/- SD optical density by HSV-2 gG enzyme-linked immunosorbent assay for sera obtained from 17 infants within one week after onset of neonatal HSV-2 infection was 0.25 +/- 0.12, compared with 1.15 +/- 0.34 in cord blood sera from exposed infants who did not develop symptoms (P less than .0001 by t test).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2826604     DOI: 10.1093/infdis/157.1.164

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Periodic health examination, 1989 update: 4. Intrapartum electronic fetal monitoring and prevention of neonatal herpes simplex. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1989-12-15       Impact factor: 8.262

2.  Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity.

Authors:  Chaya D Patel; Iara M Backes; Sean A Taylor; Yike Jiang; Arnaud Marchant; Jean M Pesola; Donald M Coen; David M Knipe; Margaret E Ackerman; David A Leib
Journal:  Sci Transl Med       Date:  2019-04-10       Impact factor: 17.956

3.  Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes.

Authors:  F Diaz-Mitoma; M Ruben; S Sacks; P MacPherson; G Caissie
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

4.  Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.

Authors:  Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

5.  Evaluation of three glycoprotein G2-based enzyme immunoassays for detection of antibodies to herpes simplex virus type 2 in human sera.

Authors:  A M Eis-Hübinger; M Däumer; B Matz; K E Schneweis
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 6.  Sexually transmitted diseases in children: herpes simplex virus infection, cytomegalovirus infection, hepatitis B virus infection and molluscum contagiosum.

Authors:  A Nageswaran; G R Kinghorn
Journal:  Genitourin Med       Date:  1993-08

Review 7.  Laboratory techniques in the diagnosis of herpes simplex infection.

Authors:  R L Ashley
Journal:  Genitourin Med       Date:  1993-06

8.  Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy.

Authors:  M Arvaja; M Lehtinen; P Koskela; M Lappalainen; J Paavonen; T Vesikari
Journal:  Sex Transm Infect       Date:  1999-06       Impact factor: 3.519

Review 9.  Genital herpes: review of the epidemic and potential use of type-specific serology.

Authors:  R L Ashley; A Wald
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Seroreactive recombinant herpes simplex virus type 2-specific glycoprotein G.

Authors:  D L Parkes; C M Smith; J M Rose; J Brandis; S R Coates
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.